AACR 2023


Brentuximab Vedotin | Solid Tumors | Poster #3253

CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors

Enfortumab Vedotin | Preclinical | Abstract #LB246

Enfortumab vedotin, a Nectin-4-directed antibody-drug conjugate, demonstrates compelling antitumor activity in non-muscle invasive bladder cancer models and accurately predicts minimal systemic exposure when administered by intravesical instillation in patients

Tisotumab Vedotin | SCCHN | Abstract #CT164

Tisotumab vedotin in squamous cell carcinoma of head and neck: interim analysis from innovaTV 207

Tucatinib | Breast Cancer | Abstract #CT065

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial-in-progress)

Tucatinib | GI Cancer | Poster #5060

Tucatinib does not alter oxaliplatin PK or associated renal function: An OCT2/MATE transport inhibition study

Disitamab Vedotin | Abstract #560

Disitamab vedotin, an investigational HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical cancer models

SGN-BB228 | Poster #5676

SGN-BB228, a CD228-directed costimulatory antibody anticalin bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T-cell exhaustion

SGN-B6A | Poster #1522

SGN-B6A induces immunogenic cell death as an additional mechanism of action

TLR7/8 | Poster #1542

Generation of an antibody-drug conjugate-optimized TLR7/8 agonist payload

SEA-TGT | Advanced Malignancies | Abstract #CT265

Phase 1 dose-escalation study of SEA-TGT monotherapy in patients with advanced malignancies (SGNTGT-001)

SEA-TGT | Abstract #5668

Using a clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD)

SEA-TGT | Abstract #6361

A preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody

Discovery Research | Poster #4890

A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent antitumor activity in colorectal cancer models

Discovery Research | Poster #2013

Oxidized anthracycline payloads induce antitumor immunogenic cell death and show linker-dependent tolerability when delivered as ADCs

Discovery Research | Poster#2656

Reversible chemical modification of antibodies: A complementary approach to tuning FcγR binding that maintains antitumor activity while mitigating peripheral immune activation

Discovery Research | Poster #4892

MMAE drives immunomodulatory changes in a preclinical xenograft model that are distinct from other clinical-stage ADC payloads